Crescent Biopharma, Inc. (CBIO) insider trading.
In Q3 2026, insiders at Crescent Biopharma, Inc. reported 10 non-derivative transactions on 8 Forms 3, 4 and 5: 1 open-market purchase worth $12.4M and 9 sales worth $286K.
- Transactions
- 10
- Purchases (P)
- 1
- Sales (S)
- 9
- Net shares, P minus S
- 836,724
- Insiders
- 8
- Last filed
- 2026-09-18
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| McNeill Jonathan | Officer · President and COO | 2 | 0 | 2 |
| Brumm Joshua T | Director, Officer · Chief Executive Officer | 2 | 0 | 2 |
| Bispham Barbara Harlin | Officer · See Remarks | 1 | 0 | 1 |
| Scalzo Richard William | Officer · Chief Financial Officer | 1 | 0 | 1 |
| Im Ellie Eunkyung | Officer · Chief Medical Officer | 1 | 0 | 1 |
| Pinkas Jan | Officer · Chief Scientific Officer | 1 | 0 | 1 |
| Lynch Ryan | Officer · See Remarks | 1 | 0 | 1 |
| Fairmount Healthcare Fund II L.P. / Kiselak Tomas / Fairmount Funds Management LLC / Harwin Peter Evan | Director, TenPercentOwner | 1 | 1 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-18 | McNeill Jonathan | S (D) | 3,839 | $16.71 | 134,588 | Form 4 |
| 2026-09-18 | Brumm Joshua T | S (D) | 7,837 | $16.71 | 271,765 | Form 4 |
| 2026-09-16 | McNeill Jonathan | S (D) | 731 | $17.9 | 138,427 | Form 4 |
| 2026-09-16 | Brumm Joshua T | S (D) | 1,610 | $17.9 | 279,602 | Form 4 |
| 2026-09-16 | Bispham Barbara Harlin | S (D) | 620 | $17.9 | 18,710 | Form 4 |
| 2026-09-16 | Scalzo Richard William | S (D) | 568 | $17.9 | 19,730 | Form 4 |
| 2026-09-16 | Im Ellie Eunkyung | S (D) | 623 | $17.9 | 21,446 | Form 4 |
| 2026-09-16 | Pinkas Jan | S (D) | 658 | $17.9 | 21,581 | Form 4 |
| 2026-09-16 | Lynch Ryan | S (D) | 240 | $17.9 | 13,631 | Form 4 |
| 2026-07-16 | Fairmount Healthcare Fund II L.P. / Kiselak Tomas / Fairmount Funds Management LLC / Harwin Peter Evan | P (A) | 853,450 | $14.5 | 3,601,316 | Form 4 |
Transaction codes in this quarter
Get CBIO insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1253689&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · CBIO company page · Crescent Biopharma, Inc. on SEC.gov
Questions
Are insiders buying or selling Crescent Biopharma, Inc. (CBIO)?
In Q3 2026, insiders at Crescent Biopharma, Inc. reported 10 non-derivative transactions on 8 Forms 3, 4 and 5: 1 open-market purchase worth $12.4M and 9 sales worth $286K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Crescent Biopharma, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/cbio.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.